Otsuka's Avanir agrees to pay $108M over Neudexta kickbacks probe

Avanir has reached a settlement with the feds over a marketing and kickbacks probe for Neudexta. Instead of marketing the med within its approved use, authorities said Avanir promoted the drug for dementia patients in long-term care facilities.